Background: The interim analysis of the multicentre New EPOC trial in patients with resectable colorectal liver metastasis showed a significant reduction in progression-free survival in patients allocated to cetuximab plus chemotherapy compared with those given chemotherapy alone. The focus of the present analysis was to assess the effect on overall survival. Methods: New EPOC was a multicentre, open-label, randomised, controlled, phase 3 trial. Adult patients (aged ≥18 years) with KRAS wild-type (codons 12, 13, and 61) resectable or suboptimally resectable colorectal liver metastases and a WHO performance status of 0–2 were randomly assigned (1:1) to receive chemotherapy with or without cetuximab before and after liver resection. Randomisa...
BACKGROUND: The addition of cetuximab (CTX) to perioperative chemotherapy (CT) for operable colorect...
In patients with unresectable colorectal liver metastases (CLM) resistant to first-line chemother-ap...
Purpose. Our study analyses clinical trials and evaluates the efficacy of adding cetuximab in system...
Background: The interim analysis of the multicentre New EPOC trial in patients with resectable color...
BACKGROUND: The interim analysis of the multicentre New EPOC trial in patients with resectable color...
BACKGROUND: Surgery for colorectal liver metastases results in an overall survival of about 40% at 5...
Background: In the Medical Research Council (MRC) COIN trial, the epidermal growth factor receptor (...
SummaryBackgroundIn the Medical Research Council (MRC) COIN trial, the epidermal growth factor recep...
BACKGROUND: In the Medical Research Council (MRC) COIN trial, the epidermal growth factor receptor (...
Background: In the Medical Research Council (MRC) COIN trial, the epidermal growth factor receptor (...
Background: In the Medical Research Council (MRC) COIN trial, the epidermal growth factor receptor (...
BACKGROUND: In the Medical Research Council (MRC) COIN trial, the epidermal growth factor receptor (...
Background The addition of cetuximab (CTX) to perioperative chemotherapy (CT) for operable colorecta...
Background:We assessed the effectiveness of cetuximab plus chronomodulated irinotecan, 5-fluorouraci...
Background: The addition of cetuximab (CTX) to perioperative chemotherapy (CT) for operable colorect...
BACKGROUND: The addition of cetuximab (CTX) to perioperative chemotherapy (CT) for operable colorect...
In patients with unresectable colorectal liver metastases (CLM) resistant to first-line chemother-ap...
Purpose. Our study analyses clinical trials and evaluates the efficacy of adding cetuximab in system...
Background: The interim analysis of the multicentre New EPOC trial in patients with resectable color...
BACKGROUND: The interim analysis of the multicentre New EPOC trial in patients with resectable color...
BACKGROUND: Surgery for colorectal liver metastases results in an overall survival of about 40% at 5...
Background: In the Medical Research Council (MRC) COIN trial, the epidermal growth factor receptor (...
SummaryBackgroundIn the Medical Research Council (MRC) COIN trial, the epidermal growth factor recep...
BACKGROUND: In the Medical Research Council (MRC) COIN trial, the epidermal growth factor receptor (...
Background: In the Medical Research Council (MRC) COIN trial, the epidermal growth factor receptor (...
Background: In the Medical Research Council (MRC) COIN trial, the epidermal growth factor receptor (...
BACKGROUND: In the Medical Research Council (MRC) COIN trial, the epidermal growth factor receptor (...
Background The addition of cetuximab (CTX) to perioperative chemotherapy (CT) for operable colorecta...
Background:We assessed the effectiveness of cetuximab plus chronomodulated irinotecan, 5-fluorouraci...
Background: The addition of cetuximab (CTX) to perioperative chemotherapy (CT) for operable colorect...
BACKGROUND: The addition of cetuximab (CTX) to perioperative chemotherapy (CT) for operable colorect...
In patients with unresectable colorectal liver metastases (CLM) resistant to first-line chemother-ap...
Purpose. Our study analyses clinical trials and evaluates the efficacy of adding cetuximab in system...